A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
Summary
- Eligibility
- for people ages 18-85 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Peter Ljubenkov
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Peter Ljubenkov
Assistant Professor, Neurology. Authored (or co-authored) 19 research publications.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Alector Inc.
- ID
- NCT03987295
- Phase
- Phase 2
- Study Type
- Interventional
- Last Updated